Lipid management in cardiovascular disease prevention guidelines: Strategies and tactics for implementation

Atherosclerosis

Volumn 196, Issue 2, 2008, Pages 532-541

  Erhardt, Leif R ^a   Leiter, Lawrence A ^b   Richard Hobbs, F D ^c  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Barriers; Cardiovascular disease (CVD); Cholesterol; Guidelines; Implementation; Prevention

Indexed keywords

AMLODIPINE; ANTILIPEMIC AGENT; ATORVASTATIN; ENALAPRIL; HYPOCHOLESTEROLEMIC AGENT; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; HEALTH CARE POLICY; HEALTH SURVEY; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; REVIEW; RISK ASSESSMENT;

ANTILIPEMIC AGENTS; AUSTRALIA; CANADA; CARDIOVASCULAR DISEASES; EUROPE; GUIDELINE ADHERENCE; HEALTH EDUCATION; HUMANS; LIPIDS; RISK ASSESSMENT; UNITED STATES;

EID: 38349093579     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.05.017     Document Type: Review

References (29)

1. Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Third report of the national cholesterol education program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001;285:2486-97.
2. De Backer G., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice, third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil 10 (2003) S1-S10
3. Smith S.C., Jackson R., Pearson T.A., et al. Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Foundation. Circulation 109 (2004) 3112-3121
4. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
5. LaRosa J.C., Grundy S.M., Waters D.D., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352 (2005) 1425-1435
6. Erhardt L.R., Pearson T.A., Bruckert E., et al. Guidelines and their implementation: a discussion document focused on the best approaches to drive improvement. Vasc Dis Prev 1 (2004) 167-174
7. World Health Organization. Global burden of disease estimates 2002. Available at: http://www.who.int/healthinfo/statistics/gbdwhosubregionmortality2002.xls. Accessed October 14, 2004.
8. EUROASPIRE, and A European society of cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE study group. European action on secondary prevention through intervention to reduce events. Eur Heart J 18 (1997) 1569-1582
9. EUROASPIRE II study group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II euro heart survey programme. Eur Heart J 22 (2001) 554-572
10. Pyorala K., De Backer G., Graham I., Poole-Wilson P., and Wood D. Prevention of coronary heart disease in clinical practice. Recommendations of the task force of the European society of cardiology, European atherosclerosis society and European society of hypertension. Eur Heart J 15 (1994) 1300-1331
11. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998;19:1434-503.
12. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II group. European action on secondary prevention by intervention to reduce events. Lancet 2001;357:995-1001.
13. Vale M.J., Jelinek M.V., Best J.D., and COACH study group. How many patients with coronary heart disease are not achieving their risk-factor targets? Experience in Victoria 1996-1998 versus 1999-2000. Med J Aust 176 (2002) 211-215
14. Pearson T.A., Laurora I., Chu H., and Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 160 (2000) 459-467
15. Leiter L, Betteridge D.J. The AUDIT study: a worldwide survey of physician attitudes about diabetic dyslipidemia. Poster presented at: American diabetes association 64th annual scientific sessions; June 4-8, 2004. Orlando, FL.
16. Hobbs F.D., and Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the reassessing European attitudes about cardiovascular treatment (REACT) survey. Fam Pract 19 (2002) 596-604
17. Erhardt L., and Hobbs F.D. Public perceptions of cardiovascular risk in five European countries: the REACT survey. Int J Clin Pract 56 (2002) 638-644
18. Cabana M.D., Rand C.S., Powe N.R., et al. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 282 (1999) 1458-1465
19. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
20. Consoli S.M., and Bruckert B.E. Educational level has a major impact on the representations of cholesterol: a study in 1579 hypercholesterolemic patients. Prev Med 38 (2004) 323-329
21. Department of Health. The National service framework for coronary heart disease. Winning the war on heart disease: progress report 2004. London: Department of health publications; 2004. Available at: www.dh.gov.uk/PolicyAndGuidance/HealthAndSocialCareTopics/CoronaryHeartDisease/fs/en. Accessed May 4, 2004.
22. Yan A.T., Tan M., Fitchett D., et al. One-year outcome of patients after acute coronary syndromes (from the Canadian acute coronary syndromes registry). Am J Cardiol 94 (2004) 25-29
23. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
24. Fitchett D.H., Leiter L.A., Tardif J.C., Goodman S.G., and Langer A. Are Canadian guidelines for cholesterol lowering in high-risk patients optimal?. Can J Cardiol 21 (2005) 85-90
25. Backlund L. How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients?. Prim Health Care Res Dev 5 (2004) 145-152
26. Chobanian A.V., Bakris G.L., Black H.R., et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289 (2003) 2560-2572
27. Emberson J.R., Whincup P.H., Morris R.W., and Walker M. Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: impact of regression dilution bias. Eur Heart J 24 (2003) 1719-1726
28. Nissen S., Tuzcu E.M., Libby P., et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 292 (2004) 2217-2226
29. World Health Organization. Integrated management of cardiovascular risk: report of a WHO meeting, Geneva, 9-12 July 2002. Geneva: World Health Organization; 2002. ISBN 92 4 156224 2.